A replay of the call will be available at the same web addresses.

About HLTH Corporation

HLTH Corporation (Nasdaq: HLTH) owns 84% of WebMD Health Corp. (Nasdaq: WBMD). WebMD is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through its public and private online portals and health-focused publications. HLTH also owns Porex, a developer, manufacturer and distributor of proprietary porous plastic products and components used in healthcare, industrial and consumer applications.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. WebMD Health Corp. is a subsidiary of HLTH Corporation (Nasdaq: HLTH).

All statements contained in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on HLTH's and WebMD's current plans and expectations and involve risks and uncertainties, including those described in our SEC filings.

SOURCE HLTH Corporation; WebMD Health Corp.

http://www.hlth.com

Consolidated Financial Highlights

Revenue for the first quarter was $81.7 million, an increase of 14% over the prior year. Earnings before interest, taxes, non-cash and other items ("Adjusted EBITDA") for the first quarter was $10.7 million, an increase of 81% over the prior year. Income from continuing operations for the first quarter was $459.6 million or $2.03 per share and net income was $463.2 million or $2.04 per share, both of which include a gain of $538 million, or approximately $514 million net of tax, from the sale of HLTH's 48% minority interest in Emdeon Business Services and a $60.1 million impairment charge related to a reduction in fair value of the Company's auction rate securities (ARS) investments.

HLTH's financial results present the ViPS and Porex businesses as discontinued operations in the current and prior year periods, reflecting the decision to divest these businesses. WebMD's offline professional medical reference and textbook publication business is presented as a discontinued operation in the prior year period, reflecting the sale of that business on December 31, 2007.

Segment Operating Results

WebMD's Online Services segment revenue was $78.4 million for the first quarter compared to $68.4 million in the prior year period, an increase of 15%. Advertising and sponsorship revenue increased 18% to $56.1 million. Private portal licensing revenue increased 9% to $21.9 million. Online Services segment Adjusted EBITDA increased 27% to $16.5 million compared to $13.0 million in the prior year period.

WebMD's Publishing and Other Services segment revenue was $3.3 million for the first quarter compared to $3.5 million in the prior year period, a decrease of 7%. Publishing and Other Services segment Adjusted EBITDA was a loss of ($0.8) million compared to a loss of ($0.4) million in the prior year period.

Sale of Investment in Emdeon Business Services

As previously reported, HLTH sold its 48% interest in Emdeon Business Services for $575 million in cash on February 8, 2008. HLTH realized a gain of $514 million, net of tax, on the sale.

Investment in Auction Rate Securities

At March 31, 2008, HLTH held auction rate securities with a face amount of $363.0 million. The types of ARS investments that HLTH owns are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. Since February, all auctions involving these securities have failed. The result of a failed auction is that these ARS continue to pay interest in accordance with their terms until the next successful auction; however liquidity will be limited until there is a successful auction or until such time as other markets for these ARS investments develop. It is uncertain when an auction market will develop. HLTH has determined that the fair value of the ARS as of March 31, 2008 was $302.8 million. Accordingly, HLTH has recorded an impairment charge of $60.1 million related to these securities in its results for the quarter ended March 31, 2008.

At March 31, 2008, in addition to HLTH's $302.8 million in ARS holdings, of which $141 million are attributable to WebMD, HLTH has approximately $1.1 billion in cash and cash equivalents, of which $160 million is attributable to WebMD.

Merger with WebMD

As previously announced, HLTH and WebMD entered into a definitive merger agreement on February 20, 2008. The agreement provided that HLTH will be merged into WebMD, with each outstanding share of HLTH common stock to be converted into 0.1979 shares of WebMD common stock and $6.89 in cash, subject to certain adjustments. Completion of the merger is conditioned upon, among other things, approval of the stockholders of both HLTH and WebMD. HLTH and WebMD currently expect to file a preliminary proxy statement/prospectus relating to the merger in the next few weeks and believe that would likely allow them to hold stockholder meetings in September to seek those approvals. However, the ability to schedule these meetings will depend on the timing for closing the sales of HLTH's ViPS and Porex businesses, at least one of which must be completed prior to closing the merger, as well as the timing for completion of SEC review of the proxy statement/prospectus. HLTH is currently in the process of selling the ViPS and Porex businesses, with potential purchasers nearing completion of their due diligence investigations.

Financial Guidance

HLTH is not providing financial guidance for 2008 at this time. WebMD provided financial guidance in a separate press release issued today.

Analyst and Investor Conference Call

As previously announced, HLTH Corporation and WebMD Health Corp. will host a conference call at 4:45 pm (Eastern) today to discuss their respective first quarter results. Investors can access the call via webcast at www.hlth.com (in the Investor Relations section). A replay of the call will be available at the same web address.

About HLTH

HLTH Corporation (NASDAQ: HLTH) is the majority holder of WebMD Health Corp. (NASDAQ: WBMD). WebMD is the leading provider of health information services for consumers, physicians, healthcare professionals, employers and health plans through its public and private online portals and health-focused publications. HLTH also owns ViPS and Porex. ViPS provides healthcare data management, analytics, decision-support and process automation solutions and related information technology services to governmental, Blue Cross Blue Shield and commercial healthcare payers. ViPS' solutions and services help its clients improve patient outcomes, increase customer satisfaction and reduce costs. Porex is a developer, manufacturer and distributor of proprietary porous plastic products and components used in healthcare, industrial and consumer applications.

This press release does not constitute an offer of any securities for sale. In connection with the proposed merger, HLTH and WebMD expect to file, with the SEC, a proxy statement/prospectus as part of a registration statement regarding the proposed transaction. Investors and security holders are urged to read the proxy statement/prospectus because it will contain important information about HLTH and WebMD and the proposed transaction. Investors and security holders may obtain a free copy of the definitive proxy statement/prospectus and other documents when filed by HLTH and WebMD with the SEC at www.sec.gov or www.hlth.com or www.wbmd.com. Investors and security holders are urged to read the proxy statement, prospectus and other relevant material when they become available before making any voting or investment decisions with respect to the merger.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: expectations regarding the market for HLTH's and WebMD's investments in auction rate securities (ARS); HLTH's and WebMD's future financial results and other measures of WebMD's future performance; market opportunities and WebMD's ability to capitalize on them; the benefits expected from new products or services and from other potential sources of additional revenue; the merger transaction between HLTH and WebMD (the "Merger Transaction"); and the potential sales transactions with respect to ViPS and Porex (the "Potential Sales Transactions"). These statements speak only as of the date of this press release, are based on HLTH's and WebMD's current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward- looking statements. These risks and uncertainties include those relating to: changes in the markets for ARS; market acceptance of WebMD's products and services; WebMD's relationships with customers and strategic partners; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries. Further information about these matters can be found in our other Securities and Exchange Commission filings. In addition, there can be no assurances regarding: whether HLTH and WebMD will be able to complete the Merger Transaction or as to the timing of such transaction; or whether HLTH will be able to complete the Potential Sales Transactions or as to the timing or terms of such transactions. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures. The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an "Explanation of Non-GAAP Financial Measures" is attached to this press release as Annex A.

WebMD(R), WebMD Health(R), POREX(R) and ViPS(SM) are trademarks of HLTH Corporation or its subsidiaries.

Emdeon(tm) and Emdeon Business Services(tm) are trademarks of Emdeon Business Services, LLC or its subsidiaries.

                               -Tables Follow-



                                HLTH CORPORATION
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share data, unaudited)

                                                       Three Months Ended
                                                           March 31,
                                                     2008             2007

    Revenue                                         $81,682          $71,881

    Costs and expenses:
      Cost of operations                             31,570           28,618
      Sales and marketing                            25,830           22,870
      General and administrative                     21,144           28,443
      Depreciation and amortization                   6,888            6,325
      Interest income                                11,936            9,674
      Interest expense                                4,607            4,709
      Gain on sale of EBS Master LLC                538,024              -
      Impairment of auction rate
       securities                                    60,108              -
      Transition services income, net                    50            2,456
      Other (expense) income, net                    (4,194)             426
    Income (loss) from continuing
     operations before income
     tax provision (benefit)                        477,351           (6,528)
      Income tax provision (benefit)                 25,614             (231)
      Minority interest in WHC (loss)
       income                                        (3,845)             115
      Equity in earnings of EBS Master LLC            4,007            7,099
    Income from continuing operations               459,589              687
      Income from discontinued operations
          (net of tax $2,910 and $1,221 in
           2008 and 2007)                             3,569            5,015
    Net income                                     $463,158           $5,702

    Basic income per common share:
      Income from continuing operations               $2.52            $0.00
      Income from discontinued operations              0.02             0.03
    Net income                                        $2.54            $0.03

    Diluted income per common share:
      Income from continuing operations               $2.03            $0.00
      Income from discontinued operations              0.01             0.03
    Net income                                        $2.04            $0.03

    Weighted-average shares outstanding
     used in computing income per common share:
          Basic                                     182,175          176,011
          Diluted                                   228,159          186,355



                                 HLTH CORPORATION
                         CONSOLIDATED SEGMENT INFORMATION
                 (In thousands, except per share data, unaudited)

                                                        Three Months Ended
                                                             March 31,
                                                     2008               2007
    Revenue
      WebMD Online Services:
        Advertising and sponsorship                 $56,065           $47,421
        Licensing                                    21,923            20,115
        Content syndication and other                   417               884
      Total WebMD Online Services                    78,405            68,420
      WebMD Publishing and Other Services             3,277             3,524
      Inter-segment eliminations                        -                 (63)
                                                    $81,682           $71,881
    Earnings (loss) before interest,
     taxes, non-cash and other items
     ("Adjusted EBITDA")
      WebMD Online Services                         $16,531           $12,992
      WebMD Publishing and Other Services              (754)             (358)
      Corporate                                      (5,059)           (6,726)
                                                    $10,718            $5,908

      Adjusted EBITDA per diluted common
       share (a)                                      $0.05             $0.03

    Interest, taxes, non-cash and other
     items (b)
      Depreciation and amortization                 $(6,888)          $(6,325)
      Non-cash stock-based compensation              (5,972)           (9,182)
      Non-cash advertising                           (1,558)           (2,320)
      Interest income                                11,936             9,674
      Interest expense                               (4,607)           (4,709)
      Gain on sale of EBS Master LLC                538,024               -
      Income tax (provision) benefit                (25,614)              231
      Minority interest in WHC loss
       (income)                                       3,845              (115)
      Equity in earnings of EBS Master LLC            4,007             7,099
      Impairment of auction rate securities         (60,108)              -
      Other (expense) income, net                    (4,194)              426
    Income from continuing operations               459,589               687
      Income from discontinued
       operations, net of tax                         3,569             5,015
    Net income                                     $463,158            $5,702

    Basic income per common share:
      Income from continuing operations               $2.52             $0.00
      Income from discontinued operations              0.02              0.03
    Net income                                        $2.54             $0.03

    Diluted income per common share:
      Income from continuing operations               $2.03             $0.00
      Income from discontinued operations              0.01              0.03
    Net income                                        $2.04             $0.03

    Weighted-average shares outstanding
     used in computing income per common share:
          Basic                                     182,175           176,011
          Diluted                                   228,159           186,355

    (a)  Adjusted EBITDA per diluted common share is based on the
         weighted-average shares outstanding used in computing diluted
         income per common share.
    (b)  Reconciliation of Adjusted EBITDA to net income (see Annex A -
         Explanation of Non-GAAP Financial Measures).



                                HLTH CORPORATION
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                            (In thousands, unaudited)

                                                        Three Months Ended
                                                            March 31,
                                                     2008              2007
    Cash flows from operating activities:
     Net income                                    $463,158           $5,702
     Adjustments to reconcile net income
      to net cash provided by (used in)
      operating activities:
       Income from discontinued
        operations, net of tax                       (3,569)          (5,015)
       Depreciation and amortization                  6,888            6,325
       Minority interest in WHC (loss) income        (3,845)             115
       Equity in earnings of EBS Master LLC          (4,007)          (7,099)
       Amortization of debt issuance costs              743              721
       Non-cash advertising                           1,558            2,320
       Non-cash stock-based compensation              5,972            9,182
       Deferred income taxes                          5,389                2
       Gain on sale of EBS                         (538,024)            (399)
       Impairment of auction rate securities         60,108              -
       Changes in operating assets and
        liabilities:
         Accounts receivable                         12,220            2,185
         Prepaid expenses and other, net             17,493              421
         Accrued expenses and other long-
          term liabilities                           10,320          (46,158)
         Deferred revenue                            11,714            7,678
          Net cash provided by (used in)
           continuing operations                     46,118          (24,020)
          Net cash (used in) provided by
           discontinued operations                   (3,751)           6,712
          Net cash provided by (used in)
           operating activities                      42,367          (17,308)

    Cash flows from investing activities:
      Proceeds from maturities and sales
       of available-for-sale securities             104,518           67,922
      Purchases of available-for-sale
       securities                                  (177,150)         (65,932)
      Purchases of property and equipment            (2,662)          (4,780)
      Proceeds related to sales of EBS,
       EPS and ACS/ACP, net of fees                 598,935            2,898
      Decrease in net advances to EBS
       Master LLC                                     1,195           19,691
          Net cash provided by continuing
           operations                               524,836           19,799
          Net cash used in discontinued
           operations                                (1,438)            (847)
          Net cash provided by investing
           activities                               523,398           18,952

    Cash flows from financing activities:
      Proceeds from issuance of HLTH and
       WHC common stock                               1,777           63,404
      Purchases of treasury stock under
       repurchase program                               -            (11,322)
          Net cash provided by continuing
           operations                                 1,777           52,082
          Net cash used in discontinued
           operations                                   (46)             (43)
          Net cash provided by financing
           activities                                 1,731           52,039
    Effect of exchange rates on cash                  1,753              184
    Net increase in cash and cash
     equivalents                                    569,249           53,867
    Cash and cash equivalents at
     beginning of period                            536,879          614,691
    Cash and cash equivalents at
     end of period                               $1,106,128         $668,558



                                 HLTH CORPORATION
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                             (In thousands, unaudited)

                                          March 31, 2008    December 31, 2007
    Assets
    Cash and cash equivalents                 $1,106,128             $536,879
    Marketable securities                        309,256              290,858
    Accounts receivable, net                      73,861               86,081
    Due from EBS Master LLC                           28                1,224
    Prepaid expenses and other current
     assets                                       27,781               71,090
    Assets of discontinued operations            266,591              262,964
            Total current assets               1,783,645            1,249,096

    Marketable equity securities                   2,036                2,383
    Property and equipment, net                   47,883               49,554
    Goodwill                                     214,623              217,323
    Intangible assets, net                        33,766               36,314
    Investment in EBS Master LLC                       -               25,261
    Other assets                                  59,922               71,466
    Total Assets                              $2,141,875           $1,651,397

    Liabilities and Stockholders' Equity
    Accrued expenses                             $59,002              $49,598
    Deferred revenue                              88,114               76,401
    Liabilities of discontinued
     operations                                  113,397              123,131
          Total current liabilities              260,513              249,130

    Convertible notes                            650,000              650,000
    Other long-term liabilities                   21,214               21,137

    Minority interest in WHC                     130,231              131,353

    Stockholders' equity                       1,079,917              599,777

    Total Liabilities and Stockholders'
     Equity                                   $2,141,875           $1,651,397



                                   ANNEX A

                  Explanation of Non-GAAP Financial Measures

The accompanying HLTH Corporation press release and financial tables include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures. The non-GAAP financial measures represent earnings before interest, taxes, non- cash and other items (which we refer to as "Adjusted EBITDA") and related per share amounts. Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for, "income from continuing operations" calculated in accordance with GAAP. The tables attached to the accompanying press release include reconciliations of non-GAAP financial measures to GAAP financial measures.

Adjusted EBITDA is used by HLTH's management as an additional measure of HLTH's overall performance and its reporting segments' performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period- to-period comparisons of Adjusted EBITDA help HLTH's management identify additional trends in HLTH's and its reporting segments' financial results that may not be shown solely by period-to-period comparisons of income from continuing operations. In addition, HLTH uses Adjusted EBITDA in the incentive compensation programs applicable to many of its employees in order to evaluate HLTH's performance. HLTH management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in income from continuing operations, as well as trends in those items. The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to net income that accompany our press releases containing non-GAAP financial measures, including the reconciliations contained in the tables attached to the accompanying press release.

HLTH believes that the presentation of Adjusted EBITDA is useful to investors in their analysis of HLTH's results for reasons similar to the reasons why HLTH's management finds it useful and because it helps facilitate investor understanding of decisions made by HLTH's management in light of the performance metrics used in making those decisions. In addition, as more fully described below, HLTH believes that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to income from continuing operations, helps investors make comparisons between HLTH and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is intended to provide a supplemental way of comparing HLTH with other public companies and is not intended as a substitute for comparisons based on "income from continuing operations" or "net income" calculated in accordance with GAAP. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by HLTH from Adjusted EBITDA but included in income from continuing operations:

    -- Depreciation and Amortization.  Depreciation and amortization expense
       is a non-cash expense relating to capital expenditures and intangible
       assets arising from acquisitions that are expensed on a straight-line
       basis over the estimated useful life of the related assets. HLTH
       excludes depreciation and amortization expense from Adjusted EBITDA
       because it believes (i) the amount of such expenses in any specific
       period may not directly correlate to the underlying performance of
       HLTH's business operations and (ii) such expenses can vary
       significantly between periods as a result of new acquisitions and full
       amortization of previously acquired tangible and intangible assets.
       Accordingly, HLTH believes this exclusion assists management and
       investors in making period-to-period comparisons of operating
       performance.  Investors should note that the use of tangible and
       intangible assets contributed to revenue in the periods presented and
       will contribute to future revenue generation and should also note that
       such expense will recur in future periods.

    -- Stock-Based Compensation Expense.  Stock-based compensation expense is
       a non-cash expense arising from the grant of stock-based awards to
       employees. HLTH believes that excluding the effect of stock-based
       compensation from Adjusted EBITDA assists management and investors in
       making period-to-period comparisons in its operating performance
       because it believes (i) the amount of such expenses in any specific
       period may not directly correlate to the underlying performance of
       HLTH's business operations and (ii) such expenses can vary
       significantly between periods as a result of the timing of grants of
       new stock-based awards, including grants in connection with
       acquisitions.  Additionally, HLTH believes that excluding stock-based
       compensation from Adjusted EBITDA assists management and investors in
       making meaningful comparisons between HLTH's operating performance and
       the operating performance of other companies that may use different
       forms of employee compensation or different valuation methodologies for
       their stock-based compensation.  Investors should note that stock-based
       compensation is a key incentive offered to employees whose efforts
       contributed to the operating results in the periods presented and are
       expected to contribute to operating results in future periods.
       Investors should also note that such expenses will recur in the future.

    -- Non-Cash Advertising Expense.  This expense relates to the usage of
       non-cash advertising obtained from News Corporation ("Newscorp") in
       exchange for equity securities issued by HLTH in 2000. The advertising
       is available only on various Newscorp properties, primarily its
       television network and cable channels without any cash cost to HLTH.
       The amount of advertising that can be used in any year is subject to
       annual contractual limitation and expires in 2010. HLTH does not incur
       any other cash expenses related to airing of television advertising.
       HLTH excludes this expense from Adjusted EBITDA (i) because it is a
       non-cash expense, (ii) because it is incremental to other non-
       television cash advertising expense that HLTH otherwise incurs, (iii)
       because HLTH has not and believes it will not incur cash expenses
       relating to television advertising in the future and (iv) to assist
       management and investors in comparing its operating results over
       multiple periods.  Investors should note that it is likely that HLTH
       derives some benefit from such advertising and that such expenses will
       recur in the future.

    -- Interest Income and Expense.  Interest income is associated with the
       level of marketable debt securities and other interest bearing accounts
       in which HLTH invests, as well as with interest expenses arising from
       the capital structure of HLTH.  Interest income and expense varies over
       time due to a variety of financing transactions and due to acquisitions
       and divestitures that HLTH has entered into or may enter into in the
       future.  HLTH has, in the past several years, issued convertible
       debentures and preferred stock, repurchased shares in cash tender
       offers and through other repurchase transactions, conducted an initial
       public offering of equity in its WebMD subsidiary and completed the
       divestiture of certain businesses. HLTH excludes interest income and
       interest expense from Adjusted EBITDA (i) because these items are not
       directly attributable to the performance of HLTH's business operations
       and, accordingly, their exclusion assists management and investors in
       making period-to-period comparisons of operating performance and (ii)
       to assist management and investors in making comparisons to companies
       with different capital structures. Investors should note that interest
       income and expense will recur in future periods.

    -- Income Tax Provision.  HLTH had a net operating loss (NOL) carryforward
       of approximately $1.3 billion as of the year ended December 31, 2007.
       HLTH maintained a full valuation allowance on these NOL carryforwards
       until the fourth quarter of 2007, at which time a portion of the
       valuation allowance was reversed after consideration of the relevant
       factors.  The related valuation allowances are either reversed through
       the income statement, additional paid-in capital, or reversed to
       goodwill, to the extent those tax benefits were acquired through
       business combinations.  The timing of such reversals has not been
       consistent and as a result, HLTH's income tax expense can fluctuate
       significantly from period to period in a manner not directly related to
       HLTH's operating performance.  HLTH excludes the income tax provision
       from Adjusted EBITDA (i) because it believes that the income tax
       provision is not directly attributable to the underlying performance of
       HLTH's business operations and, accordingly, its exclusion assists
       management and investors in making period-to-period comparisons of
       operating performance and (ii) to assist management and investors in
       making comparisons to companies with different tax attributes.
       Investors should note that income tax provision will recur in future
       periods.

    -- Minority Interest in WHC.  This represents the minority stockholders'
       proportionate share of net income of HLTH's majority-owned WebMD Health
       Corp. subsidiary (which we refer to as WHC).  The size of this Minority
       Interest is related to HLTH's percentage ownership of WHC.  Changes in
       that percentage ownership may result from changes in WHC's capital
       structure, including as a result of sales of WHC equity securities by
       WHC or HLTH or as a result of exercise of WHC employee stock options.
       HLTH excludes Minority Interest from Adjusted EBITDA (i) because it
       believes that the size of the Minority Interest can vary for reasons
       not attributable to the underlying performance of HLTH's business
       operations and, accordingly, its exclusion assists management and
       investors in making period-to-period comparisons of operating
       performance and (ii) to assist management and investors in making
       comparisons to companies with different capital structures. Investors
       should note that Minority Interest in WHC will recur in future periods.

    -- Other Items.  HLTH engages in other activities and transactions that
       can impact HLTH's overall income from continuing operations.  These
       other items included, but were not limited to, (i) legal expenses
       relating to the on-going Department of Justice investigation, (ii)
       equity in earnings of EBS Master LLC, which represents 48% of EBS's
       income through February 8, 2008, (iii) working capital adjustment from
       the sale of 52% of the Emdeon Business Services segment on November 16,
       2006, (iv) a reduction of certain sales and use tax contingencies
       resulting from the expiration of certain applicable statutes of
       limitations, (v) advisory expenses relating to the evaluation, in 2008
       and 2007, by HLTH's Board of Directors of strategic alternatives for
       HLTH, (vi) gain on sale from the sale of the remaining 48% ownership
       interest in EBS Master LLC and (vii) loss on the impairment of auction
       rate securities.  HLTH excludes these other items from Adjusted EBITDA
       because it believes these activities or transactions are not directly
       attributable to the performance of HLTH's business operations and,
       accordingly, their exclusion assists management and investors in making
       period-to-period comparisons of operating performance.  Investors
       should note that these other items may recur in future periods.

SOURCE HLTH Corporation

http://www.hlth.com

Financial Summary

Revenue for the first quarter was $81.7 million compared to $71.9 million in the prior year period, an increase of 14%. Earnings before interest, taxes, depreciation, amortization, and other non-cash items ("Adjusted EBITDA") for the first quarter increased 25% to $15.8 million or $0.27 per share compared to $12.6 million or $0.21 per share in the prior year period.

Loss from continuing operations and net loss for the first quarter was $(23.3) million or $(0.40) per share, which includes a $27.4 million impairment charge related to a reduction in fair value of the Company's auction rate securities investments. Excluding the impairment, income from continuing operations and net income was $4.1 million or $0.07 per share for the first quarter compared to $0.7 million or $0.01 per share in the prior year period.

Operating Highlights

Online Services segment revenue was $78.4 million for the first quarter compared to $68.4 million in the prior year period, an increase of 15%. Advertising and sponsorship revenue increased 18% to $56.1 million. Private portal licensing revenue increased 9% to $21.9 million. Online Services segment Adjusted EBITDA increased 27% to $16.5 million compared to $13.0 million in the prior year period.

Traffic to the WebMD Health Network continued to expand with the average number of unique users reaching a record 51.9 million per month and total traffic of 1.2 billion page views during the first quarter, increases of 25% and 24%, respectively, from a year ago. Excluding the prior year period's traffic from AOL (which ceased to be part of The WebMD Health Network on April 30, 2007), the average monthly unique users of the WebMD Health Network increased 29% and page view traffic increased 27%. In the first quarter, 1.1 million continuing medical education (CME) programs were completed on the WebMD Professional Network, an increase of 64% from the prior year period.

WebMD continued to expand its base of large employers and health plans utilizing its private Health and Benefits portals during the first quarter, bringing total platform customers to 122 from 103 a year ago. The installed base of companies licensing the WebMD private portal platform now includes: Newell Rubbermaid, Herman Miller, Inc., SummaCare, Inc. and QualCare, Inc.

Publishing and Other Services segment revenue was $3.3 million for the first quarter compared to $3.5 million in the prior year period, a decrease of 7%. Publishing and Other Services segment Adjusted EBITDA was a loss of ($0.8) million compared to a loss of ($0.4) million in the prior year period. WebMD's offline professional medical reference and textbook publication business was sold on December 31, 2007 and is reflected as a discontinued operation in the Company's financial statements for prior periods.

The strength of the WebMD brand continues to expand. WebMD the Magazine is now the third most highly read health magazine, behind only Prevention and Men's Health, according to the 2008 MARS OTC/DTC national media and marketing study released in April.

Investment in Auction Rate Securities

At March 31, 2008, WebMD held auction rate securities (ARS) with a face amount of $168.4 million. The types of ARS investments that WebMD owns are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. Since February, all auctions involving these securities have failed. The result of a failed auction is that these ARS continue to pay interest in accordance with their terms until the next successful auction; however liquidity will be limited until there is a successful auction or until such time as other markets for these ARS investments develop. It is uncertain when other markets will develop. WebMD has determined that the fair value of the ARS as of March 31, 2008 was $141 million. Accordingly, WebMD has recorded an impairment charge of $27.4 million related to a reduction in fair value of the Company's auction rate securities investments for the quarter ended March 31, 2008.

In addition to its ARS investments, WebMD has approximately $160 million in cash and cash equivalents at March 31, 2008.

Merger with HLTH

As previously announced, HLTH and WebMD entered into a definitive merger agreement on February 20, 2008. The agreement provided that HLTH will be merged into WebMD, with each outstanding share of HLTH common stock to be converted into 0.1979 shares of WebMD common stock and $6.89 in cash, subject to certain adjustments. Completion of the merger is conditioned upon, among other things, approval of the stockholders of both HLTH and WebMD. HLTH and WebMD currently expect to file a preliminary proxy statement/prospectus relating to the merger in the next few weeks and believe that would likely allow them to hold stockholder meetings in September to seek those approvals. However, the ability to schedule these meetings will depend on the timing for closing the sales of HLTH's ViPS and Porex businesses, at least one of which must be completed prior to closing the merger, as well as the timing for completion of SEC review of the proxy statement/prospectus. HLTH is currently in the process of selling the ViPS and Porex businesses, with potential purchasers nearing completion of their due diligence investigations.

Financial Guidance

As announced on April 23, 2008, WebMD currently expects 2008 revenue of $380 to $395 million, assuming the following distribution:

    -- Approximately 73% from advertising and sponsorship, with revenue growth
       of approximately 21% to 26% over 2007;
    -- Approximately 23% from licensing of our private portal products, with
       revenue growth of approximately 8% to 10% over 2007; and
    -- Approximately 4% from publishing and content syndication revenues.

A schedule providing additional information is attached to this press release.

Analyst and Investor Conference Call

As previously announced, WebMD will hold a conference call with investors and analysts to discuss its first quarter results at 4:45 pm (eastern) today. The call can be accessed at www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

About WebMD

WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. WebMD Health Corp. is a subsidiary of HLTH Corporation (Nasdaq: HLTH).

The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList and theHeart.org.

This press release does not constitute an offer of any securities for sale. In connection with the proposed merger, HLTH and WebMD expect to file, with the SEC, a proxy statement/prospectus as part of a registration statement regarding the proposed transaction. Investors and security holders are urged to read the proxy statement/prospectus because it will contain important information about HLTH and WebMD and the proposed transaction. Investors and security holders may obtain a free copy of the definitive proxy statement/prospectus and other documents when filed by HLTH and WebMD with the SEC at www.sec.gov or www.hlth.com or www.wbmd.com. Investors and security holders are urged to read the proxy statement, prospectus and other relevant material when they become available before making any voting or investment decisions with respect to the merger.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: expectations regarding the market for WebMD's investments in auction rate securities (ARS); WebMD's future financial results and other measures of WebMD's future performance; market opportunities and WebMD's ability to capitalize on them; the benefits expected from new products or services and from other potential sources of additional revenue; the merger transaction between HLTH and WebMD (the "Merger Transaction"); and the potential sales transactions with respect to ViPS and Porex (the "Potential Sales Transactions"). These statements speak only as of the date of this press release, are based on WebMD's current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: changes in the markets for ARS; market acceptance of WebMD's products and services; WebMD's relationships with customers and strategic partners; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries. Further information about these matters can be found in our other Securities and Exchange Commission filings. In addition, there can be no assurances regarding: whether HLTH and WebMD will be able to complete the Merger Transaction or as to the timing of such transaction; or whether HLTH will be able to complete the Potential Sales Transactions or as to the timing or terms of such transactions. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures. The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an "Explanation of Non-GAAP Financial Measures" is attached to this press release as Annex A.

WebMD(R), WebMD Health(R), Medscape(R), eMedicine(R), MedicineNet(R), RxList(R), Subimo(R), Medsite(R), The Little Blue Book(R) and Summex(R), are trademarks of WebMD Health Corp. or its subsidiaries.

                              WEBMD HEALTH CORP.
                    CONSOLIDATED STATEMENTS OF OPERATIONS
               (In thousands, except per share data, unaudited)

                                                       Three Months Ended
                                                             March 31,
                                                      2008             2007

    Revenue                                         $81,682          $71,944

    Costs and expenses:
        Cost of operations                           31,570           28,618
        Sales and marketing                          25,830           22,870
        General and administrative                   13,775           15,505
        Impairment of auction rate securities        27,406              -
        Depreciation and amortization                 6,785            5,991
        Interest income                               3,453            1,985
    Income (loss) from continuing operations
     before income tax provision                    (20,231)             945
        Income tax provision                          3,104              210
    Income (loss) from continuing operations        (23,335)             735
        Loss from discontinued operations,
         net of tax                                     -                (29)
    Net income (loss)                              $(23,335)            $706

    Basic income (loss) per common share:
        Income (loss) from continuing operations     $(0.40)           $0.01
        Loss from discontinued operations               -              (0.00)
    Net Income (loss)                                $(0.40)           $0.01


    Diluted income (loss) per common share:
        Income (loss) from continuing operations     $(0.40)           $0.01
        Loss from discontinued operations               -              (0.00)
    Net Income (loss)                                $(0.40)           $0.01

    Weighted-average shares outstanding used in
     computing basic and diluted net income
     (loss) per common share:
        Basic                                        57,636           56,976
        Diluted                                      57,636           59,630



                              WEBMD HEALTH CORP.
                       CONSOLIDATED SEGMENT INFORMATION
               (In thousands, except per share data, unaudited)

                                                       Three Months Ended
                                                            March 31,
                                                      2008             2007
    Revenue
      Online Services:
          Advertising and sponsorship               $56,065          $47,421
          Licensing                                  21,923           20,115
          Content syndication and other                 417              884
        Total Online Services                        78,405           68,420
      Publishing and Other Services                   3,277            3,524
                                                    $81,682          $71,944
    Earnings (loss) before interest, taxes,
     depreciation, amortization and other
     non-cash items ("Adjusted EBITDA") (a)
      Online Services                               $16,531          $12,992
      Publishing and Other Services                    (754)            (358)
                                                     15,777           12,634

          Adjusted EBITDA per basic common
           share                                      $0.27            $0.22
          Adjusted EBITDA per diluted common
           share ( c )                                $0.27            $0.21

    Interest, taxes, depreciation, amortization
     and other non-cash items (b)
        Interest income                               3,453            1,985
        Depreciation and amortization                (6,785)          (5,991)
        Non-cash advertising                         (1,558)          (2,320)
        Non-cash stock-based compensation            (3,712)          (5,363)
        Impairment of auction rate securities       (27,406)             -
        Income tax provision                         (3,104)            (210)
    Income (loss) from continuing operations        (23,335)             735
        Loss from discontinued operations,
         net of tax                                     -                (29)
    Net income (loss)                              $(23,335)            $706

    Basic income (loss) per common share:
        Income (loss) from continuing
         operations                                  $(0.40)           $0.01
        Loss from discontinued operations               -              (0.00)
    Net Income (loss)                                $(0.40)           $0.01

    Diluted income (loss) per common share:
        Income (loss) from continuing
         operations                                  $(0.40)           $0.01
        Loss from discontinued operations               -              (0.00)
    Net Income (loss)                                $(0.40)           $0.01

    Weighted-average shares outstanding
     used in computing basic and diluted net
     income (loss) per common share:
        Basic                                        57,636           56,976
        Diluted                                      57,636           59,630


    (a) See Annex A - Explanation of Non-GAAP Financial Measures

    (b) Reconciliation of Adjusted EBITDA to net income (loss)

    (c) Three months ended March 31, 2008 Adjusted EBITDA per share is
        calculated based on 59,145 diluted shares.



                              WEBMD HEALTH CORP.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                          (In thousands, unaudited)

                                                 March 31,        December 31,
                                                   2008               2007
    ASSETS
    Current assets:
     Cash and cash equivalents                   $159,831           $213,753
     Marketable securities                        141,044             80,900
     Accounts receivable, net                      73,861             86,081
     Current portion of prepaid
      advertising                                   2,275              2,329
     Due from HLTH                                    -                1,153
     Other current assets                           8,837             10,840
      Total current assets                        385,848            395,056

    Property and equipment, net                    46,995             48,589
    Prepaid advertising                             3,017              4,521
    Goodwill                                      221,429            221,429
    Intangible assets, net                         33,766             36,314
    Other assets                                   10,889             12,955
                                                 $701,944           $718,864

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
     Accrued expenses                             $16,731            $26,498
     Deferred revenue                              88,114             76,401
     Due to HLTH                                      207                -
      Total current liabilities                   105,052            102,899

    Other long-term liabilities                     9,033              9,210

    Stockholders' equity                          587,859            606,755
                                                 $701,944           $718,864



                              WEBMD HEALTH CORP.
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                          (In thousands, unaudited)

                                                           Year Ended
                                                            March 31,
                                                       2008            2007
    Cash flows from operating activities:
     Net income (loss)                              $(23,335)           $706
     Adjustments to reconcile net income to
      net cash provided by operating activities:
       Loss from discontinued operations, net
        of tax                                           -                29
       Depreciation and amortization                   6,785           5,991
       Non-cash advertising                            1,558           2,320
       Non-cash stock-based compensation               3,712           5,363
       Deferred income taxes                           2,415              78
       Impairment of auction rate securities          27,406             -
       Changes in operating assets and
        liabilities:
            Accounts receivable                       12,220           2,185
            Other assets                                (164)            (66)
            Accrued expenses and other
             long-term liabilities                    (8,949)        (11,545)
            Due to HLTH                                1,329             228
            Deferred revenue                          11,714           7,678
                Net cash provided by
                 continuing operations                34,691          12,967
                Net cash provided by
                 discontinued operations                 -                54
                Net cash provided by
                 operating activities                 34,691          13,021

    Cash flows from investing activities:
     Proceeds from maturities and sales
      of available-for-sale securities                40,350          28,122
     Purchases of available-for-sale
      securities                                    (127,900)        (48,632)
     Purchases of property and equipment              (2,637)         (4,762)
     Cash received from sale of business,
      net of fees                                        985             -
                Net cash used in investing
                 activities                          (89,202)        (25,272)

    Cash flows from financing activities:
     Proceeds from issuance of common stock              589           4,458
     Net cash transfers with HLTH                        -           145,257
                Net cash provided by
                 financing activities                    589         149,715

    Net (decrease) increase in cash and
     cash equivalents                                (53,922)        137,464

    Cash and cash equivalents at beginning of
     period                                          213,753          44,660
    Cash and cash equivalents at end of period      $159,831        $182,124



                          FINANCIAL GUIDANCE SUMMARY
                           2008 Financial Guidance
                   (in millions, except per share amounts)

                                                          Year Ended
                                                        December 31, 2008
                                                              Range
       Revenue                                      $380.0            $395.0

       Earnings before interest, taxes,
        depreciation, amortization and
        other non-cash items ("Adjusted
        EBITDA") (a)                                 $97.5            $107.5

       Adjusted EBITDA per diluted common
        share                                        $1.57             $1.73

       Interest, taxes, depreciation,
        amortization and other non-cash
        items (b)
       Interest income                               $10.0             $11.0
       Depreciation and amortization                $(31.0)           $(29.0)
       Non-cash advertising                          $(5.0)            $(5.0)
       Non-cash stock-based compensation            $(22.0)           $(21.0)
       Impairment of auction rate
        securities                                  $(27.4)           $(27.4)
       Income tax provision (c)                     $(20.0)           $(26.0)

       Net income                                     $2.1             $10.1

       Net income per common share:
       Basic                                         $0.04             $0.17
       Diluted                                       $0.03             $0.16

       Net income, excluding impairment
        of auction rate securities of
        ($27.4) (d)                                  $29.5             $37.5

       Net income per common share,
        excluding impairment of auction
        rate securities
       Basic                                         $0.50             $0.64
       Diluted                                       $0.48             $0.60

       Weighted-average shares
        outstanding used in computing net
        income per common share:
       Basic                                          59.0              59.0
       Diluted                                        62.0              62.0


    Notes:
    (a)  See Annex A - Explanation of Non-GAAP Financial Measures

    (b)  Reconciliation of Adjusted EBITDA to net income

    (c)  Income tax rate for Q2 to Q4 2008 is estimated to be
         approximately 41% of pretax income. The income tax provision excludes
         any benefit relating to any reversal in 2008 of the valuation
         allowance against deferred tax assets.

    (d)  Impairment of auction rate securities recorded in Q1 2008.


    Additional Information
    -- Quarterly distribution of revenue is estimated to be approximately
       $81.7 in Q1, $88 to $90 in Q2, $100 to $104 in Q3 and $110 to $119 in
       Q4
    -- Adjusted EBITDA as a percentage of revenue is estimated to be
       approximately 19% in Q1, 22% to 23% in Q2, 27% to 28% in Q3 and 32% to
       35% in Q4
    -- Net Income (loss) as a percentage of revenue is estimated to be
       approximately (29.0%) in Q1, 6.0% to 7.0% in Q2, 9.0% to 11.0% in Q3
       and 10.0% to 14.0% in Q4



                                   ANNEX A

                  Explanation of Non-GAAP Financial Measures
                      (All dollar amounts in thousands)

The accompanying WebMD Health Corp. press release and financial tables include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures. The non-GAAP financial measures represent earnings before interest, taxes, depreciation, amortization and other non-cash items (which we refer to as "Adjusted EBITDA") and related per share amounts. Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for, "income (loss) from continuing operations" calculated in accordance with GAAP. The tables attached to the accompanying press release include reconciliations of non-GAAP financial measures to GAAP financial measures.

Adjusted EBITDA is used by WebMD's management as an additional measure of WebMD's overall performance and its reporting segments' performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help WebMD's management identify additional trends in WebMD's and its reporting segments' financial results that may not be shown solely by period-to-period comparisons of income (loss) from continuing operations. In addition, WebMD uses Adjusted EBITDA in the incentive compensation programs applicable to many of its employees in order to evaluate WebMD's performance. WebMD management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in income (loss) from continuing operations, as well as trends in those items. The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to net income (loss) from continuing operations that accompany our press releases containing non-GAAP financial measures, including the reconciliations contained in the tables attached to the accompanying press release.

WebMD believes that the presentation of Adjusted EBITDA is useful to investors in their analysis of WebMD's results for reasons similar to the reasons why WebMD's management finds it useful and because it helps facilitate investor understanding of decisions made by WebMD's management in light of the performance metrics used in making those decisions. In addition, as more fully described below, WebMD believes that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to income (loss) from continuing operations, helps investors make comparisons between WebMD and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is intended to provide a supplemental way of comparing WebMD with other public companies and is not intended as a substitute for comparisons based on "income (loss) from continuing operations" or "net income" calculated in accordance with GAAP. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by WebMD from Adjusted EBITDA but included in income (loss) from continuing operations:

    -- Depreciation and Amortization.  Depreciation and amortization expense
       is a non-cash expense relating to capital expenditures and intangible
       assets arising from acquisitions that are expensed on a straight-line
       basis over the estimated useful life of the related assets. WebMD
       excludes depreciation and amortization expense from Adjusted EBITDA
       because it believes (i) the amount of such expenses in any specific
       period may not directly correlate to the underlying performance of
       WebMD's business operations and (ii) such expenses can vary
       significantly between periods as a result of new acquisitions and full
       amortization of previously acquired tangible and intangible assets.
       Accordingly, WebMD believes this exclusion assists management and
       investors in making period-to-period comparisons of operating
       performance.  Investors should note that use of tangible and intangible
       assets contributed to revenue in the periods presented and will
       contribute to future revenue generation and should also note that such
       expenses will recur in future periods.

    -- Stock-Based Compensation Expense.  Stock-based compensation expense is
       a non-cash expense arising from the grant of stock-based awards to
       employees. WebMD believes that excluding the effect of stock-based
       compensation from Adjusted EBITDA assists management and investors in
       making period-to-period comparisons in its operating performance
       because it believes (i) the amount of such expenses in any specific
       period may not directly correlate to the underlying performance of
       WebMD's business operations and (ii) such expenses can vary
       significantly between periods as a result of the timing of grants of
       new stock-based awards, including grants in connection with
       acquisitions.  Additionally, WebMD believes that excluding stock-based
       compensation from Adjusted EBITDA assists management and investors in
       making meaningful comparisons between WebMD's operating performance and
       the operating performance of other companies that may use different
       forms of employee compensation or different valuation methodologies for
       their stock-based compensation.  Investors should note that stock-based
       compensation is a key incentive offered to employees whose efforts
       contributed to the operating results in the periods presented and are
       expected to contribute to operating results in future periods.
       Investors should also note that such expenses will recur in the future.
       Stock-based compensation expenses included in the Statement of
       Operations are summarized as follows:


                                             Three Months Ended
                                                  March 31,
                                           2008               2007

    Non-cash stock-based compensation
     included in:
      Cost of operations                 $(1,119)           $(1,578)
      Sales and marketing                $(1,138)           $(1,258)
      General and administrative         $(1,455)           $(2,527)


    -- Non-Cash Advertising Expense.  This expense relates to the usage of
       non-cash advertising obtained from News Corporation ("Newscorp") in
       exchange for equity securities issued by our parent, HLTH Corporation
       in 2000. The advertising is available only on various Newscorp
       properties, primarily its television network and cable channels without
       any cash cost to WebMD. The amount of advertising that can be used in
       any year is subject to annual contractual limitation and expires in
       2009. WebMD does not incur any other cash expenses related to airing of
       television advertising. WebMD excludes this expense from Adjusted
       EBITDA (i) because it is a non-cash expense, (ii) because it is
       incremental to other non-television cash advertising expense that WebMD
       otherwise incurs, (iii) because WebMD has not and believes it will not
       incur cash expenses relating to television advertising in the future
       and (iv) to assist management and investors in comparing its operating
       results over multiple periods.  Investors should note that it is likely
       that WebMD derives some benefit from such advertising and that such
       expenses will recur in the future.  Non-cash advertising expenses
       included in the Consolidated Statement of Operations in Sales and
       Marketing expense were $1,558 and $2,320 for the three months ended
       March 31, 2008 and 2007, respectively.

    -- Interest Income.  Interest income is associated with the level of
       marketable debt securities and other interest bearing accounts in which
       WebMD invests.  Interest income varies over time due to varying levels
       of securities available for investment.  Transactions that WebMD has
       entered into in recent periods that have impacted securities available
       for investment include the initial public offering of equity in WebMD
       and acquisitions of other companies for varying amounts of cash since
       our initial public offering.  Additional financing transactions as well
       as potential acquisitions that WebMD may enter into in the future could
       impact the levels and timing of securities available for investment.
       WebMD excludes interest income from Adjusted EBITDA (i) because it is
       not directly attributable to the performance of WebMD's business
       operations and, accordingly, its exclusion assists management and
       investors in making period-to-period comparisons of operating
       performance and (ii) to assist management and investors in making
       comparisons to companies with different capital structures. Investors
       should note that interest income will recur in future periods.

    -- Income Tax Provision.  WebMD had a net operating loss (NOL)
       carryforward of approximately $270,000 as of the year ended December
       31, 2007.  WebMD maintained a full valuation allowance on these NOL
       carryforwards until the fourth quarter of 2007, at which time a portion
       of the valuation allowance was reversed after consideration of the
       relevant factors.  The related valuation allowances are either reversed
       through the income statement, additional paid-in capital, or reversed
       to goodwill, to the extent those tax benefits were acquired through
       business combinations.  The timing of such reversals has not been
       consistent and as a result, WebMD's income tax expense can fluctuate
       significantly from period to period in a manner not directly related to
       WebMD's operating performance.  WebMD excludes the income tax provision
       from Adjusted EBITDA (i) because it believes that the income tax
       provision is not directly attributable to the underlying performance of
       WebMD's business operations and, accordingly, its exclusion assists
       management and investors in making period-to-period comparisons of
       operating performance and (ii) to assist management and investors in
       making comparisons to companies with different tax attributes.
       Investors should note that income tax provision will recur in future
       periods.

    -- Other Items.  WebMD engages in other activities and transactions that
       can impact WebMD's overall income (loss) from continuing operations.
       WebMD excludes these other items from Adjusted EBITDA when it believes
       these activities or transactions are not directly attributable to the
       performance of WebMD's business operations and, accordingly, their
       exclusion would assists management and investors in making
       period-to-period comparisons of operating performance.  Investors
       should note that these other items may recur in future periods.  In the
       accompanying press release and financial tables, WebMD has excluded
       loss on the impairment of auction rate securities from Adjusted EBITDA.

SOURCE WebMD Health Corp.

http://www.webmd.com

About HLTH

HLTH Corporation (Nasdaq: HLTH) owns 84% of WebMD Health Corp. (Nasdaq: WBMD). WebMD is the leading provider of health information services for consumers, physicians, healthcare professionals, employers and health plans through its public and private online portals and health-focused publications. HLTH also owns Porex, a developer, manufacturer and distributor of proprietary porous plastic products and components used in healthcare, industrial and consumer applications.

This press release does not constitute an offer of any securities for sale. In connection with the proposed merger, HLTH and WebMD expect to file, with the SEC, a proxy statement/prospectus as part of a registration statement regarding the proposed transaction. Investors and security holders are urged to read the proxy statement/prospectus because it will contain important information about HLTH and WebMD and the proposed transaction. Investors and security holders may obtain a free copy of the definitive proxy statement/prospectus and other documents when filed by HLTH and WebMD with the SEC at www.sec.gov or www.hlth.com or www.wbmd.com. Investors and security holders are urged to read the proxy statement, prospectus and other relevant material when they become available before making any voting or investment decisions with respect to the merger.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: the merger transaction between HLTH and WebMD (the "Merger Transaction"). These statements speak only as of the date of this press release, are based on HLTH's current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and plastics industries. Further information about these matters can be found in our Securities and Exchange Commission filings. In addition, there can be no assurances: regarding whether HLTH will be able to complete the Merger Transaction or as to the timing of such transaction. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

WebMD(R), WebMD Health(R), POREX(R) and ViPS(SM) are trademarks of HLTH Corporation or its subsidiaries.

SOURCE HLTH Corporation

http://www.hlth.com